{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:08:25Z","timestamp":1788923305402,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MedScience"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s11684-026-1200-8","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:57:51Z","timestamp":1780394271000},"page":"483-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Obinutuzumab plus bendamustine as first-line therapy for indolent B-cell lymphomas: a prospective multicenter open-label study"],"prefix":"10.1007","volume":"20","author":[{"given":"Yuting","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xixi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kejie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youchao","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengsi","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lugui","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Chinese Workshop of Indolent Lymphomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"1200_CR1","first-page":"177","volume-title":"Atlas of Diagnostic Hematology E-Book","author":"Lymphoma SL","year":"2020","unstructured":"Lymphoma SL. B-Cell Chronic Lymphoid Leukemias. In: Atlas of Diagnostic Hematology E-Book. Amsterdam: Elsevier; 2020: 177"},{"issue":"6","key":"1200_CR2","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/10428194.2025.2456970","volume":"66","author":"PL Fedele","year":"2025","unstructured":"Fedele PL, Opat S. Indolent lymphoma: addressing the needs of survivors. Leuk Lymphoma 2025; 66(6): 1021\u20131035","journal-title":"Leuk Lymphoma"},{"key":"1200_CR3","first-page":"100325","volume":"17","author":"G Amhaz","year":"2022","unstructured":"Amhaz G, Bazarbachi A, El-Cheikh J. Immunotherapy in indolent non-Hodgkin\u2019s lymphoma. Leuk Res Rep 2022; 17: 100325","journal-title":"Leuk Res Rep"},{"key":"1200_CR4","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/B978-0-443-19200-5.00014-2","volume-title":"Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal","author":"J Wang","year":"2024","unstructured":"Wang J, Qin R, Jin Y, Xia B, Xu J. Therapeutic options for rituximab-resistant patients. In: Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal. Amsterdam: Elsevier; 2024: 211\u2013230"},{"issue":"2","key":"1200_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s12325-016-0451-1","volume":"34","author":"K Tobinai","year":"2017","unstructured":"Tobinai K, Klein C, Oya N, Fingerle-Rowson G. A Review of obinutuzumab (GA101), a novel type II anti-CD20 monoclonal antibody, for the treatment of patients with B-cell malignancies. Adv Ther 2017; 34(2): 324\u2013356","journal-title":"Adv Ther"},{"issue":"26","key":"1200_CR6","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.2217\/fon-2022-0112","volume":"18","author":"A Davies","year":"2022","unstructured":"Davies A, Kater AP, Sharman JP, Stilgenbauer S, Vitolo U, Klein C, Parreira J, Salles G. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review. Future Oncol 2022; 18(26): 2943\u20132966","journal-title":"Future Oncol"},{"issue":"23","key":"1200_CR7","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","volume":"36","author":"W Hiddemann","year":"2018","unstructured":"Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, D\u00fcrig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol 2018; 36(23): 2395\u20132404","journal-title":"J Clin Oncol"},{"issue":"8","key":"1200_CR8","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J, Dueck G, Trn\u011bn\u00fd M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 2016; 17(8): 1081\u20131093","journal-title":"Lancet Oncol"},{"issue":"1","key":"1200_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canep.2014.12.001","volume":"39","author":"Y Li","year":"2015","unstructured":"Li Y, Wang Y, Wang Z, Yi D, Ma S. Racial differences in three major NHL subtypes: descriptive epidemiology. Cancer Epidemiol 2015; 39(1): 8\u201313","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"1200_CR10","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/cam4.2028","volume":"8","author":"SJ Wu","year":"2019","unstructured":"Wu SJ, Chen YC, Lo WC, Chiang CJ, Lin CT, Chuang SS, Lai MS. Distinctive incidence patterns of follicular lymphoma in Taiwan: implications of ethnic differences. Cancer Med 2019; 8(4): 1899\u20131907","journal-title":"Cancer Med"},{"issue":"1","key":"1200_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ijc.28343","volume":"134","author":"M Iwanaga","year":"2014","unstructured":"Iwanaga M, Chiang CJ, Soda M, Lai MS, Yang YW, Miyazaki Y, Matsuo K, Matsuda T, Sobue T. Incidence of lymphoplasmacytic lymphoma\/Waldenstr\u00f6m\u2019s macroglobulinaemia in Japan and Chinese Taiwan population-based cancer registries, 1996\u20132003. Int J Cancer 2014; 134(1): 174\u2013180","journal-title":"Int J Cancer"},{"issue":"4","key":"1200_CR12","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1097\/PDM.0b013e3182585c3c","volume":"21","author":"Y Pan","year":"2012","unstructured":"Pan Y, Meng B, Sun B, Guan B, Liang Y, Wang H, Hao X, Fu K. Frequencies of BCL2 and BCL6 translocations in representative Chinese follicular lymphoma patients: morphologic, immunohistochemical, and FISH analyses. Diagn Mol Pathol 2012; 21(4): 234\u2013240","journal-title":"Diagn Mol Pathol"},{"issue":"3","key":"1200_CR13","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1097\/HS9.0000000000000699","volume":"6","author":"M Herold","year":"2022","unstructured":"Herold M, Hoster E, Janssens A, McCarthy H, Tedeschi A, Pocock C, Rosta A, Trn\u011bn\u00fd M, Nielsen TG, Knapp A, Hiddemann W, Marcus R. Immunochemotherapy and maintenance with obinutuzumab or rituximab in patients with previously untreated marginal zone lymphoma in the randomized GALLIUM trial. HemaSphere 2022; 6(3): e699","journal-title":"HemaSphere"},{"issue":"2","key":"1200_CR14","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1053\/j.seminhematol.2023.03.009","volume":"60","author":"SP Treon","year":"2023","unstructured":"Treon SP, Tedeschi A, San-Miguel J, Garc\u00eda-Sanz R, Anderson KC, Kimby E, Minnema MC, Benevolo G, Qiu L, Yi S, Terpos E, Tam CS, Castillo JJ, Morel P, Dimopoulos M, Owen RG. Report of consensus Panel 4 from the 11th International Workshop on Waldenstr\u00f6m\u2019s macroglobulinemia on diagnostic and response criteria. Semin Hematol 2023; 60(2): 97\u2013106","journal-title":"Semin Hematol"},{"issue":"23","key":"1200_CR15","doi-asserted-by":"publisher","first-page":"5483","DOI":"10.1158\/1078-0432.CCR-23-3939","volume":"30","author":"Y Yan","year":"2024","unstructured":"Yan Y, Yu Y, Xiong W, Wang J, Yao Y, Jia Y, Huang Y, Li Y, Wang T, Lyu R, Sun H, Wang H, Wang Q, Liu W, An G, Sui W, Xu Y, Huang W, Yu Z, Zou D, Hao M, Xiao Z, Wang J, Qiu L, Yi S. Determination of MYD88 and CXCR4 mutations for clinical detection and their significance in Waldenstr\u00f6m macroglobulinemia. Clin Cancer Res 2024; 30(23): 5483\u20135493","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1200_CR16","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1038\/s41375-021-01124-5","volume":"35","author":"S Yi","year":"2021","unstructured":"Yi S, Yan Y, Jin M, Xiong W, Yu Z, Yu Y, Cui R, Wang J, Wang Y, Lin Y, Jia Y, Zhang D, Wang T, Lv R, Liu W, Sui W, Huang W, Fu M, Xu Y, Deng S, An G, Zou D, Li Z, Shi J, Xiao Z, Wang J, Cheng T, Gale RP, Wang L, Qiu L. High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia. Leukemia 2021; 35(8): 2412\u20132415","journal-title":"Leukemia"},{"issue":"31","key":"1200_CR17","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1200\/JCO.19.01073","volume":"37","author":"E Bachy","year":"2019","unstructured":"Bachy E, Seymour JF, Feugier P, Offner F, L\u00f3pez-Guillermo A, Belada D, Xerri L, Catalano JV, Brice P, Lemonnier F, Martin A, Casasnovas O, Pedersen LM, Dorvaux V, Simpson D, Leppa S, Gabarre J, da Silva MG, Glaisner S, Ysebaert L, Vekhoff A, Intragumtornchai T, Le Gouill S, Lister A, Estell JA, Milone G, Sonet A, Farhi J, Zeuner H, Tilly H, Salles G. Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA Study. J Clin Oncol 2019; 37(31): 2815\u20132824","journal-title":"J Clin Oncol"},{"issue":"7","key":"1200_CR18","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1002\/cncr.35137","volume":"130","author":"Y Chu","year":"2024","unstructured":"Chu Y, Liu Y, Yu Z, Zhan L, Lu T, Jiang Y, Fang X, Zhou X, Wang X. Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: a systematic review and network meta-analysis of randomized trials. Cancer 2024; 130(7): 1072\u20131082","journal-title":"Cancer"},{"issue":"1","key":"1200_CR19","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s40880-019-0403-7","volume":"39","author":"SY Oh","year":"2019","unstructured":"Oh SY, Kim WS, Kim JS, Kim SJ, Yoon DH, Yang DH, Lee WS, Kim HJ, Yhim HY, Jeong SH, Won JH, Lee S, Kong JH, Lim SN, Ji JH, Kwon KA, Lee GW, Lee JH, Lee HS, Shin HJ, Suh C. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Cancer Commun (Lond) 2019; 39(1): 58","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"1200_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/bjh.15148","volume":"181","author":"JJ Castillo","year":"2018","unstructured":"Castillo JJ, Gustine JN, Meid K, Dubeau TE, Severns P, Xu L, Yang G, Hunter ZR, Treon SP. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenstr\u00f6m macroglobulinaemia. Br J Haematol 2018; 181(1): 77\u201385","journal-title":"Br J Haematol"},{"issue":"13","key":"1200_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.2217\/fon-2020-0071","volume":"16","author":"A Grunenberg","year":"2020","unstructured":"Grunenberg A, Kaiser LM, Woelfle S, Schmelzle B, Viardot A, M\u00f6ller P, Barth TF, Muche R, Dreyhaupt J, Buske C. Phase II trial evaluating the efficacy and safety of the anti-CD20 monoclonal antibody obinutuzumab in patients with marginal zone lymphoma. Future Oncol 2020; 16(13): 817\u2013825","journal-title":"Future Oncol"},{"issue":"15","key":"1200_CR22","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.2217\/fon-2016-0084","volume":"12","author":"J Edelmann","year":"2016","unstructured":"Edelmann J, Gribben JG. Obinutuzumab for the treatment of indolent lymphoma. Future Oncol 2016; 12(15): 1769\u20131781","journal-title":"Future Oncol"},{"issue":"2","key":"1200_CR23","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3960\/jslrt.21031","volume":"62","author":"M Suzuki","year":"2022","unstructured":"Suzuki M, Koyama D, Ikeda S, Sukegawa M, Teshirogi M, Misawa K, Tsunoda S. Serum IgG and lymphocyte counts are useful for the early detection of infection in patients receiving bendamustine-rituximab therapy. J Clin Exp Hematop 2022; 62(2): 91\u201398","journal-title":"J Clin Exp Hematop"},{"issue":"14","key":"1200_CR24","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, Phillips E, Sangha R, Schlag R, Seymour JF, Townsend W, Trn\u011bn\u00fd M, Wenger M, Fingerle-Rowson G, Rufibach K, Moore T, Herold M, Hiddemann W. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 2017; 377(14): 1331\u20131344","journal-title":"N Engl J Med"},{"issue":"1","key":"1200_CR25","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41408-023-00897-5","volume":"13","author":"D Ikeda","year":"2023","unstructured":"Ikeda D, Fukumoto A, Uesugi Y, Tabata R, Miura D, Narita K, Takeuchi M, Watari T, Otsuka Y, Matsue K. Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease. Blood Cancer J 2023; 13(1): 133","journal-title":"Blood Cancer J"},{"key":"1200_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/IDR.S396271","volume":"16","author":"A Onishi","year":"2023","unstructured":"Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, Nishiyama D, Shimura K, Kaneko H, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J. Impact of treatment with anti-CD20 monoclonal antibody on the production of neutralizing antibody against anti-SARS-CoV-2 vaccination in mature B-cell neoplasms. Infect Drug Resist 2023; 16: 509\u2013519","journal-title":"Infect Drug Resist"},{"issue":"5","key":"1200_CR27","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1007\/s12185-022-03305-z","volume":"115","author":"K Narita","year":"2022","unstructured":"Narita K, Nakaji S, Tabata R, Terao T, Kuzume A, Tsushima T, Ikeda D, Fukumoto A, Miura D, Takeuchi M, Doi M, Umezawa Y, Otsuka Y, Takamatsu H, Matsue K. Antibody response to COVID-19 vaccination in patients with lymphoma. Int J Hematol 2022; 115(5): 728\u2013736","journal-title":"Int J Hematol"},{"issue":"1","key":"1200_CR28","doi-asserted-by":"publisher","first-page":"27576","DOI":"10.1038\/s41598-024-79173-w","volume":"14","author":"Q Jiang","year":"2024","unstructured":"Jiang Q, Lin F, Li Z, Duan H, Jiang C, Yu X, Wang C, Zhang L, Sun X, Zha J, Liu L, Lin Z, Xu B. Changes of T cell subsets across treatments associated with prognosis in newly diagnosed follicular lymphoma. Sci Rep 2024; 14(1): 27576","journal-title":"Sci Rep"},{"issue":"11","key":"1200_CR29","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1007\/s00277-014-2135-8","volume":"93","author":"R Garc\u00eda Mu\u00f1oz","year":"2014","unstructured":"Garc\u00eda Mu\u00f1oz R, Izquierdo-Gil A, Mu\u00f1oz A, Roldan-Galiacho V, Rabasa P, Panizo C. Lymphocyte recovery is impaired in patients with chronic lymphocytic leukemia and indolent non-Hodgkin lymphomas treated with bendamustine plus rituximab. Ann Hematol 2014; 93(11): 1879\u20131887","journal-title":"Ann Hematol"},{"issue":"17","key":"1200_CR30","doi-asserted-by":"publisher","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","volume":"117","author":"PA Moore","year":"2011","unstructured":"Moore PA, Zhang W, Rainey GJ, Burke S, Li H, Huang L, Gorlatov S, Veri MC, Aggarwal S, Yang Y, Shah K, Jin L, Zhang S, He L, Zhang T, Ciccarone V, Koenig S, Bonvini E, Johnson S. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011; 117(17): 4542\u20134551","journal-title":"Blood"},{"issue":"1","key":"1200_CR31","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41408-025-01225-9","volume":"15","author":"V Dulobdas","year":"2025","unstructured":"Dulobdas V, Kirkwood AA, Serpenti F, Gautama B, Panopoulou A, Mathew A, Gabriel S, Malladi R, Pealing J, Bonney D, Nicholson E, Besley C, Ghorashian S, Kuhnl A, Davies E, Chappell J, Black A, Menne T, O\u2019Reilly MA, Sanderson R, Chaganti S. Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel. Blood Cancer J 2025; 15(1): 30","journal-title":"Blood Cancer J"},{"issue":"2","key":"1200_CR32","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bjh.18831","volume":"202","author":"T Jo","year":"2023","unstructured":"Jo T, Yoshihara S, Okuyama Y, Fujii K, Henzan T, Kahata K, Yamazaki R, Takeda W, Umezawa Y, Fukushima K, Ashida T, Yamada-Fujiwara M, Hanajiri R, Yonetani N, Tada Y, Shimura Y, Nishikii H, Shiba N, Mimura N, Ando J, Sato T, Nakashima Y, Ikemoto J, Iwaki K, Fujiwara SI, Ri M, Nagamura-Inoue T, Tanosaki R, Arai Y. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: a nationwide survey in Japan. Br J Haematol 2023; 202(2): 256\u2013266","journal-title":"Br J Haematol"},{"issue":"1","key":"1200_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-020-01018-6","volume":"14","author":"M Lumish","year":"2021","unstructured":"Lumish M, Falchi L, Imber BS, Scordo M, von Keudell G, Joffe E. How we treat mature B-cell neoplasms (indolent B-cell lymphomas). J Hematol Oncol 2021; 14(1): 5","journal-title":"J Hematol Oncol"},{"issue":"12","key":"1200_CR34","doi-asserted-by":"publisher","first-page":"e7239","DOI":"10.1002\/cam4.7239","volume":"13","author":"J Jelicic","year":"2024","unstructured":"Jelicic J, Juul-Jensen K, Bukumiric Z, Runason Simonsen M, Roost Clausen M, Ludvigsen Al-Mashhadi A, Schou Pedersen R, Bj\u00f8rn Poulsen C, Ortved Gang A, Brown P, El-Galaly TC, Larsen TS. Revisiting beta-2 microglobulin as a prognostic marker in diffuse large B-cell lymphoma. Cancer Med 2024; 13(12): e7239","journal-title":"Cancer Med"},{"issue":"7","key":"1200_CR35","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1158\/0008-5472.CAN-10-3382","volume":"71","author":"S Josson","year":"2011","unstructured":"Josson S, Nomura T, Lin JT, Huang WC, Wu D, Zhau HE, Zayzafoon M, Weizmann MN, Gururajan M, Chung LW. \u03b22-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res 2011; 71(7): 2600\u20132610","journal-title":"Cancer Res"}],"container-title":["MedScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-026-1200-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11684-026-1200-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-026-1200-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:49:08Z","timestamp":1788922148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11684-026-1200-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1200"],"URL":"https:\/\/doi.org\/10.1007\/s11684-026-1200-8","relation":{},"ISSN":["3091-4973","3091-4981"],"issn-type":[{"value":"3091-4973","type":"print"},{"value":"3091-4981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"6 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflict of interest\n                      Yuting Yan, Xinyang Hu, Xiuhua Sun, Xixi Xiang, Yihao Wang, Tingyu Wang, Kejie Zhang, Liang Wang, Youchao Jia, Chengsi Gui, Ying Yu, Rui Lyu, Wenjie Xiong, Shuhui Deng, Wei Liu, Liang Huang, Gang An, Lugui Qiu, and Shuhua Yi declare that they have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"The study was approved by the Ethics Committee of the Institute of Hematology and Blood Diseases Hospital and performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants prior to study enrollment. The trial was registered at ClinicalTrials.gov (NCT06415708).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}